Deqi Pharmaceutical-B (06996) received an ATG-201 down payment of 60 million US dollars from UCB

Zhitong Financial App News, Deqi Pharmaceutical-B (06996) issued an announcement to conclude an exclusive global licensing agreement between the company (as the licensor) and UCB (as the licensee) for the CD19/CD3 bispecific T-cell adapter (TCE) antibody ATG-201. The Group has received an initial down payment of US$60 million from UCB. The receipt of the down payment under this landmark agreement with UCB (UCB) further consolidated the Group's cash position and provided strong financial support to advance the development of the Group's innovative drug pipeline and accelerate the benefits of more patients.